Suresh Kumar Chhetri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Suresh Kumar Chhetri has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Tahir Majeed
Preston MND Care and Research Centre, Department of Neurology, Royal Preston Hospital, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK
7 shared publications- Hedley C. A. Emsley
Department of Neurology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK
4 shared publications Rejith Dayanandan
Department of Neurology, Royal Preston Hospital, Preston, United Kingdom
4 shared publicationsSachin Mathur
Department of Neuroradiology, Royal Preston Hospital, UK
4 shared publications- Belinda Fay Bradley
University of Central Lancashire, Preston, UK
3 shared publications - Godwin Lekwuwa
MRC Human Movement and Balance Unit, Institute of Neurology, London, UK
3 shared publications
Latest Publications
- Open Access
- 24 July 2025
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 27  (1-2) , 78-89
Fatigue in amyotrophic lateral sclerosis/motor neuron disease: prevalence, influences and trajectories
Objective: In a large cohort of people with amyotrophic lateral sclerosis/motor neuron disease (pwALS), we examined the age-sex prevalence of fatigue, its relationship to other symptoms and functioning, and trajectories over time. Methods: Data from the Trajectories of Outcome in Neurological Conditions study were analyzed by Rasch analysis, structural equation and group-based trajectory models. Results: Fatigue was reported by 97.8% on Neurological Fatigue Index-MND (NFI-MND) and 96.4% on Numeric Rating Scale Fatigue among 1058 pwALS: mean age 65 (range 20-90); mean duration 23 months (range 0-301); 60.7% male; onset 26.5% Bulbar, 71.5% Limb and 2.0% Respiratory. Mean (metric) level on NFI-MND was 12.8 (SD 5.3; range 0-24). Cut-points on the NFI-MND of 10 and 15 divided fatigue into mild (27.3%); moderate (36.1%) and severe (36.2%). Structural equation modeling showed that function, cognition, spasticity, dyspnea and pain have descending order of effect. Over average 11.6 months follow-up, 60.5% had stable fatigue, 23.8% increased fatigue level, while 15.8% showed declining fatigue. Trajectory analysis showed three groups, low, average and high fatigue. Those with low trajectories had less spasticity, worry, cognitive problems, as well as better functioning, longer duration and were less likely to be male. High fatigue trajectory was associated with worse spasticity, cognition and anxiety. Conclusions: Fatigue is extremely common among pwALS, thus more work is required on fatigue management. In addition to treating fatigue itself, the current study shows that targeting cognition, spasticity, dyspnea and pain might be fruitful.
- 24 July 2025
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 27  (1-2) , 78-89
Open AccessFatigue in amyotrophic lateral sclerosis/motor neuron disease: prevalence, influences and trajectories
Objective: In a large cohort of people with amyotrophic lateral sclerosis/motor neuron disease (pwALS), we examined the age-sex prevalence of fatigue, its relationship to other symptoms and functioning, and trajectories over time. Methods: Data from the Trajectories of Outcome in Neurological Conditions study were analyzed by Rasch analysis, structural equation and group-based trajectory models. Results: Fatigue was reported by 97.8% on Neurological Fatigue Index-MND (NFI-MND) and 96.4% on Numeric Rating Scale Fatigue among 1058 pwALS: mean age 65 (range 20-90); mean duration 23 months (range 0-301); 60.7% male; onset 26.5% Bulbar, 71.5% Limb and 2.0% Respiratory. Mean (metric) level on NFI-MND was 12.8 (SD 5.3; range 0-24). Cut-points on the NFI-MND of 10 and 15 divided fatigue into mild (27.3%); moderate (36.1%) and severe (36.2%). Structural equation modeling showed that function, cognition, spasticity, dyspnea and pain have descending order of effect. Over average 11.6 months follow-up, 60.5% had stable fatigue, 23.8% increased fatigue level, while 15.8% showed declining fatigue. Trajectory analysis showed three groups, low, average and high fatigue. Those with low trajectories had less spasticity, worry, cognitive problems, as well as better functioning, longer duration and were less likely to be male. High fatigue trajectory was associated with worse spasticity, cognition and anxiety. Conclusions: Fatigue is extremely common among pwALS, thus more work is required on fatigue management. In addition to treating fatigue itself, the current study shows that targeting cognition, spasticity, dyspnea and pain might be fruitful.
- Open Access
- 20 July 2025
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 27  (1-2) , 55-61
Patient reported outcome measures require scale metrification and quantified precision: evidence from the assessment of breathlessness in people with ALS/MND
Introduction: Precision (how closely repeated measures match) and responsiveness (ability to detect change over time) are critical properties of patient reported outcome measures (PROMs). Smallest Detectable Difference (SDD) is a useful statistic regarding precision; Minimal Detectable Change (MDC) and Minimal Important Change (MIC) assess responsiveness. Methods: We examined measurement properties of Numeric Rating Scale for Breathlessness, ALSFRS-R respiratory subscale and Dyspnea-12, contributed by participants in the Trajectories of Outcome in Neurological Conditions-ALS study. Rasch analysis converts ordinal scale data to interval equivalents. Results: Data from 1120 people with ALS showed ALSFRS-R Respiratory is only valid as ordinal data. The NRS Breathlessness requires computation from a wider NRS set for Rasch analysis; its SDD is 3.2, MDC 2.59, MIC 2.39, with score range of 0-10. The Dyspnea-12 has SDD 7.0, MDC 6.14, MIC 4.5, with score range of 0-36. The %MDC, indicating smallest change detectable above measurement error as % of scale range, is superior for the Dyspnea-12 (17.1%) compared to the NRS Breathlessness (25.9%). Another advantage of Dyspnea-12 is transformation of raw ordinal to interval equivalent data using published conversion tables. Both NRS and Dyspnea-12 have disadvantages of MIC < MDC. Conclusions: Accurate measurement underpins optimal clinical decision making and high-quality research. Informed choice of PROMs reduces risk of misinterpreting clinical and research data. Patients want PROMs which they feel give an accurate account of their progression when participating in research and communicating with their clinical team. The Dyspnea-12 is preferrable for clinical and research use based on its psychometric properties.
- 20 July 2025
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 27  (1-2) , 55-61
Open AccessPatient reported outcome measures require scale metrification and quantified precision: evidence from the assessment of breathlessness in people with ALS/MND
Introduction: Precision (how closely repeated measures match) and responsiveness (ability to detect change over time) are critical properties of patient reported outcome measures (PROMs). Smallest Detectable Difference (SDD) is a useful statistic regarding precision; Minimal Detectable Change (MDC) and Minimal Important Change (MIC) assess responsiveness. Methods: We examined measurement properties of Numeric Rating Scale for Breathlessness, ALSFRS-R respiratory subscale and Dyspnea-12, contributed by participants in the Trajectories of Outcome in Neurological Conditions-ALS study. Rasch analysis converts ordinal scale data to interval equivalents. Results: Data from 1120 people with ALS showed ALSFRS-R Respiratory is only valid as ordinal data. The NRS Breathlessness requires computation from a wider NRS set for Rasch analysis; its SDD is 3.2, MDC 2.59, MIC 2.39, with score range of 0-10. The Dyspnea-12 has SDD 7.0, MDC 6.14, MIC 4.5, with score range of 0-36. The %MDC, indicating smallest change detectable above measurement error as % of scale range, is superior for the Dyspnea-12 (17.1%) compared to the NRS Breathlessness (25.9%). Another advantage of Dyspnea-12 is transformation of raw ordinal to interval equivalent data using published conversion tables. Both NRS and Dyspnea-12 have disadvantages of MIC < MDC. Conclusions: Accurate measurement underpins optimal clinical decision making and high-quality research. Informed choice of PROMs reduces risk of misinterpreting clinical and research data. Patients want PROMs which they feel give an accurate account of their progression when participating in research and communicating with their clinical team. The Dyspnea-12 is preferrable for clinical and research use based on its psychometric properties.
- 1 October 2017
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 44, 80-83
E-learning in neurology education: Principles, opportunities and challenges in combating neurophobia
- 1 October 2017
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 44, 80-83
E-learning in neurology education: Principles, opportunities and challenges in combating neurophobia
- 24 November 2016
- Published by SAGE Publications in Palliative Medicine
- Vol. 31  (7) , 676-677
Enteral feeding in motor neurone disease: Patients’ perspectives and impact on quality of life
- 24 November 2016
- Published by SAGE Publications in Palliative Medicine
- Vol. 31  (7) , 676-677
Enteral feeding in motor neurone disease: Patients’ perspectives and impact on quality of life
- Open Access
- 6 November 2016
- Published by Wiley in Case Reports in Neurological Medicine
- Vol. 2016, 1-3
An Overlapping Case of Miller Fisher Syndrome, Bickerstaff’s Encephalitis, and the ASMAN Variant of Guillain-Barre Syndrome
A 56-year-old man presented with a 3-day history of progressive tingling of the hands, unsteadiness, and diplopia. He was initially diagnosed clinically with Miller Fisher Syndrome (MFS) but later developed limb weakness consistent with Guillain-Barre Syndrome (GBS) and subsequently reduced consciousness consistent with Bickerstaff’s brainstem encephalitis (BBE). Neurophysiology revealed an axonal motor and sensory neuropathy, in keeping with the Acute Motor and Sensory Axonal Neuropathy (AMSAN) variant of GBS. We believe that our patient had an MFS-AMSAN-BBE overlap syndrome. This is supported by his glycolipid antibody profile with high titres of anti-GQ1b IgG antibody and anti-GD1a IgG antibody. Anti-GQ1b antibodies are frequently found in both MFS and BBE and the anti-GD1a antibody is associated with axonal forms of GBS. Overlapping cases of MFS and BBE are well described, and because the same antibody is often found in both conditions, it is thought that they share a common autoimmune mechanism. BBE has also been previously reported in association with GBS lending support that it also lies on the same spectrum. This overlapping case of ASMAN variant of GBS, MFS, and BBE provides further support that these conditions are part of the same spectrum.
- 6 November 2016
- Published by Wiley in Case Reports in Neurological Medicine
- Vol. 2016, 1-3
Open AccessAn Overlapping Case of Miller Fisher Syndrome, Bickerstaff’s Encephalitis, and the ASMAN Variant of Guillain-Barre Syndrome
A 56-year-old man presented with a 3-day history of progressive tingling of the hands, unsteadiness, and diplopia. He was initially diagnosed clinically with Miller Fisher Syndrome (MFS) but later developed limb weakness consistent with Guillain-Barre Syndrome (GBS) and subsequently reduced consciousness consistent with Bickerstaff’s brainstem encephalitis (BBE). Neurophysiology revealed an axonal motor and sensory neuropathy, in keeping with the Acute Motor and Sensory Axonal Neuropathy (AMSAN) variant of GBS. We believe that our patient had an MFS-AMSAN-BBE overlap syndrome. This is supported by his glycolipid antibody profile with high titres of anti-GQ1b IgG antibody and anti-GD1a IgG antibody. Anti-GQ1b antibodies are frequently found in both MFS and BBE and the anti-GD1a antibody is associated with axonal forms of GBS. Overlapping cases of MFS and BBE are well described, and because the same antibody is often found in both conditions, it is thought that they share a common autoimmune mechanism. BBE has also been previously reported in association with GBS lending support that it also lies on the same spectrum. This overlapping case of ASMAN variant of GBS, MFS, and BBE provides further support that these conditions are part of the same spectrum.
- Open Access
- 9 March 2016
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 109  (5) , 341-342
Swallow syncope unravelled by fizzy drink challenge
Conflict of interest : None declared.
- 9 March 2016
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 109  (5) , 341-342
Open AccessSwallow syncope unravelled by fizzy drink challenge
Conflict of interest : None declared.
- 1 February 2016
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 24, 47-51
Motor neurone disease in Lancashire and South Cumbria in North West England and an 8year experience with enteral nutrition
- 1 February 2016
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 24, 47-51
Motor neurone disease in Lancashire and South Cumbria in North West England and an 8year experience with enteral nutrition
- Open Access
- 22 April 2015
- Published by SAGE Publications in The Neurohospitalist
- Vol. 6  (1) , 32-35
Morvan Syndrome
A 74-year-old gentleman was admitted to the regional neurosciences center with encephalopathy, myokymia, and dysautonomia. Chest imaging had previously identified an incidental mass in the anterior mediastinum, consistent with a primary thymic tumor. Antivoltage-gated potassium channel (anti-VGKC) antibodies were positive (titer 1273 pmol/L) and he was hypokalemic. Electromyogram and nerve conduction studies were in keeping with peripheral nerve hyperexcitability syndrome, and an electroencephalogram was consistent with encephalopathy. A diagnosis of Morvan syndrome was made, for which he was initially treated with high-dose steroids, followed by a 5-day course of intravenous immunoglobulin (IVIG) therapy. He also underwent thymectomy, followed by a postexcision flare of his symptoms requiring intensive care management. Further steroids, plasmapheresis, and IVIG achieved stabilization of his clinical condition, enabling transfer for inpatient neurorehabilitation. He was commenced on azathioprine and a prolonged oral steroid taper. A subsequent presumed incipient relapse responded well to further IVIG treatment. This case report documents a thymoma-associated presentation of anti-VGKC-positive Morvan syndrome supplemented by patient and carer narrative and video, both of which provide valuable further insights into this rare disorder. There are a limited number of publications surrounding this rare condition available in the English literature. This, combined with the heterogenous presentation, association with underlying malignancy, response to treatment, and prognosis, provides a diagnostic challenge. However, the association with anti-VGKC antibody-associated complexes and 2 recent case series have provided some scope for both accurate diagnosis and management.
- 22 April 2015
- Published by SAGE Publications in The Neurohospitalist
- Vol. 6  (1) , 32-35
Open AccessMorvan Syndrome
A 74-year-old gentleman was admitted to the regional neurosciences center with encephalopathy, myokymia, and dysautonomia. Chest imaging had previously identified an incidental mass in the anterior mediastinum, consistent with a primary thymic tumor. Antivoltage-gated potassium channel (anti-VGKC) antibodies were positive (titer 1273 pmol/L) and he was hypokalemic. Electromyogram and nerve conduction studies were in keeping with peripheral nerve hyperexcitability syndrome, and an electroencephalogram was consistent with encephalopathy. A diagnosis of Morvan syndrome was made, for which he was initially treated with high-dose steroids, followed by a 5-day course of intravenous immunoglobulin (IVIG) therapy. He also underwent thymectomy, followed by a postexcision flare of his symptoms requiring intensive care management. Further steroids, plasmapheresis, and IVIG achieved stabilization of his clinical condition, enabling transfer for inpatient neurorehabilitation. He was commenced on azathioprine and a prolonged oral steroid taper. A subsequent presumed incipient relapse responded well to further IVIG treatment. This case report documents a thymoma-associated presentation of anti-VGKC-positive Morvan syndrome supplemented by patient and carer narrative and video, both of which provide valuable further insights into this rare disorder. There are a limited number of publications surrounding this rare condition available in the English literature. This, combined with the heterogenous presentation, association with underlying malignancy, response to treatment, and prognosis, provides a diagnostic challenge. However, the association with anti-VGKC antibody-associated complexes and 2 recent case series have provided some scope for both accurate diagnosis and management.
- 17 February 2015
- Published by SAGE Publications in Palliative Medicine
- Vol. 29  (7) , 667-668
Choosing the place of death: Empowering motor neurone disease/amyotrophic lateral sclerosis patients in end-of-life care decision making
- 17 February 2015
- Published by SAGE Publications in Palliative Medicine
- Vol. 29  (7) , 667-668
Choosing the place of death: Empowering motor neurone disease/amyotrophic lateral sclerosis patients in end-of-life care decision making
- 4 February 2015
- Published by SAGE Publications in Cephalalgia
- Vol. 35  (12) , 1133-1136
Fulminant acephalgic giant cell arteritis with basal cerebral artery occlusion: A radiological and clinico-pathological study
There is little in the published neurological literature on acephalgic giant cell arteritis (GCA); even less commonly reported are the clinical, radiological and pathological features of GCA presenting with ischaemic stroke and stenosis/occlusion of the basal cerebral arteries. We report a fatal case of GCA manifesting as repeated episodes of cerebral ischaemia with radiological evidence of severe stenosis involving both internal carotid and vertebral arteries and post-mortem histopathological confirmation of GCA.
- 4 February 2015
- Published by SAGE Publications in Cephalalgia
- Vol. 35  (12) , 1133-1136
Fulminant acephalgic giant cell arteritis with basal cerebral artery occlusion: A radiological and clinico-pathological study
There is little in the published neurological literature on acephalgic giant cell arteritis (GCA); even less commonly reported are the clinical, radiological and pathological features of GCA presenting with ischaemic stroke and stenosis/occlusion of the basal cerebral arteries. We report a fatal case of GCA manifesting as repeated episodes of cerebral ischaemia with radiological evidence of severe stenosis involving both internal carotid and vertebral arteries and post-mortem histopathological confirmation of GCA.